- Adrenal Cancer
- Anal Cancer
- Bile Duct Cancer
- Bladder Cancer
- Bone Cancer
- Brain and Central Nervous Cancer
- Advanced Reading
- Cancer FAQs
- Deciding on Treatment
- Managing Side Effects
- Prevention and Screening
- Understanding Your Diagnosis
- Carcinoma of Unknown Primary
- Cervical Cancer
- Colorectal Cancer
- Endometrial Cancer
- Esophageal Cancer
- Ewing Sarcoma
- Eye Cancer
- Gallbladder Cancer
- Head and Neck Cancer
- Hodgkin Disease
- Kaposi's Sarcoma
- Kidney Cancer
- Laryngeal Cancer
- Leukemia - Acute Lymphocytic Leukemia (ALL)
- Leukemia - Acute Myelocytic (AML)
- Leukemia - Chronic Lymphocytic Leukemia (CLL)
- Leukemia - Chronic Myelogenous Leukemia (CML)
- Leukemia - General
- Liver Cancer
- Lung Cancer
- Malignant Mesothelioma
- Multiple Myeloma
- Non-Hodgkin Lymphoma
- Oral Cancer
- Other Cancers
- Ovarian Cancer
- Pancreatic Cancer
- Penile Cancer
- Pituitary Cancer
- Prostate Cancer
- Skin Cancer - Melanoma
- Skin Cancer - Non-Melanoma
- Soft Tissue Sarcoma
- Stomach Cancer
- Testicular Cancer
- Thymus Cancer
- Thyroid Cancer
- Urethral Cancer
- Uterine Cancer
- Vaginal Cancer
- Vulvar Cancer
This patient summary on hypercalcemia is adapted from the PDQ summary written for health professionals by cancer experts. This and other credible information about cancer treatment, screening, prevention, supportive care, and ongoing clinical trials is available from the National Cancer Institute. Hypercalcemia is a disorder in which the level of calcium in the blood is too high. Hypercalcemia is the most common life-threatening disorder associated with cancer. This brief summary describes hypercalcemia, its causes and treatment.
This summary is about hypercalcemia in adults with cancer.
Hypercalcemia occurs in 10%-20% of people with cancer, although it occurs much less often in children. The cancers most often associated with hypercalcemia are cancer of the breast and lung, as well as certain cancers of the blood, particularly multiple myeloma. Early diagnosis and treatment with fluids and drugs that lower calcium levels in the blood can improve symptoms in a few days, but diagnosis may be difficult. Symptoms of hypercalcemia can appear gradually and may resemble symptoms of many cancers and other diseases. Early diagnosis and treatment are not only lifesaving in the short term, but may also increase the patient's ability to complete cancer therapy and improve the patient's quality of life.
Patients who have advancedterminal cancer and are no longer receiving treatment for the cancer may choose not to be treated for hypercalcemia. This option should be considered by a patient and his or her family in advance, before symptoms of hypercalcemia occur.
Normal calcium regulation
Healthy people consume about the same amount of calcium in their diet as their bodies lose in urine, feces, and sweat. Hypercalcemia associated with cancer disrupts the body's ability to maintain a normal level of calcium.
Normal, healthy kidneys are able to filter large amounts of calcium from the blood, excrete the excess not needed by the body, and retain the amount of calcium the body does need. However, hypercalcemia may cause such high levels of calcium in the body that the kidneys are overworked and become unable to excrete the excess. Some tumors produce a substance that can cause the kidneys to excrete too little calcium. This results in a large amount of urine being produced, which then causes dehydration. Dehydration may lead to appetite loss, nausea, and vomiting, which make the dehydration worse. Inactivity caused by weakness and tiredness may increase the amount of calcium in the blood by increasing the amount of calcium that is absorbed from the bones. Calcium deposits may collect in the kidneys, causing permanent damage.
The main causes of hypercalcemia due to cancer are an increase in the amount of calcium absorbed from the bones, and an inability of the kidneys to excrete excess calcium. Some cancer cells secrete substances that cause calcium to be absorbed into the bloodstream from bones. Immobility, dehydration, anorexia, nausea, and vomiting may also increase calcium levels.
There is little relationship between symptoms of hypercalcemia and the actual level of calcium in the blood. Symptoms of hypercalcemia resemble symptoms of other illnesses, making an early and rapid diagnosis difficult. The severity of the symptoms may depend on other factors, such as previous cancer treatment, reactions to drugs, or other illnesses a patient may have.
Most patients do not experience all of the symptoms of hypercalcemia, and some patients may not have any symptoms at all. However, most patients with high calcium levels in the blood do have symptoms. Some patients develop signs of hypercalcemia when calcium levels are only slightly high, while patients who have had higher calcium levels for a long time may show few symptoms.
Symptoms may be classified by the affected body part:
Calcium plays a major role in the normal functioning of the central nervous system (the brain and spinal cord). Symptoms of hypercalcemia may include weakness, loss of reflexes in the muscles, and decreased stamina. Patients with central nervous system symptoms may have changes in personality, difficulty thinking or speaking clearly, disorientation, or hallucinations. Eventually, coma may result. Headaches can also occur, which can be made worse by vomiting and dehydration.
Hypercalcemia affects normal heart rhythms and increases sensitivity to some heart medications (such as digoxin). As calcium levels increase, irregular heartbeats may develop, and may lead to a heart attack.
Increased stomach acid often is produced with hypercalcemia and may intensify loss of appetite, nausea, and vomiting. Constipation may result from the dehydration associated with hypercalcemia.
Hypercalcemia causes the kidneys to not function correctly, leading to the production of large volumes of urine. The large amount of urine combined with less liquid intake leads to symptoms of dehydration, including thirst, dry mouth, little or no sweating, and concentrated urine. Patients with myeloma often have kidney problems due to hypercalcemia. Kidney stones may result from long-term hypercalcemia.
Hypercalcemia of cancer can result from bone metastases or bone loss, and may contribute to broken bones, bone disfigurement, and pain.
Patients with high calcium levels should be examined for the following:
Kidneys (production of too much urine, night-time urinating, sugar in the urine, excess thirst).
Other (muscle and bone pain, itching).
How fast did the symptoms appear?
Is the patient taking digoxin?
Is there another disease present that could cause dehydration or lack of movement?
Are there effective treatments for the patient's cancer?
Decision to treat
The decision to treat hypercalcemia depends on the treatment goals determined by the patient, caregivers, and the physician. The natural course of untreated hypercalcemia progresses to loss of consciousness and coma. This may be preferred by some patients at the end of life who have unrelieved suffering and/or untreatable symptoms.
Patients at risk of developing hypercalcemia may be the first to recognize its symptoms, such as fatigue. Measures to prevent hypercalcemia include drinking enough fluids, controlling nausea and vomiting, walking and being active, and cautious use or elimination of drugs that can contribute to the development of hypercalcemia or affect its treatment. Calcium in the diet should not be reduced or eliminated, however, because the body's absorption of calcium is reduced in patients with hypercalcemia.
The severity of the hypercalcemia determines the amount of treatment necessary. Severe hypercalcemia should be treated immediately and aggressively. Less severe hypercalcemia should be treated according to the symptoms. Response to treatment is shown by the disappearance of the symptoms of hypercalcemia and a decrease in the level of calcium in the blood.
Mild hypercalcemia does not usually need to be treated aggressively. Patients with mild hypercalcemia and central nervous system symptoms are harder to treat. Younger patients are especially difficult to treat because they tolerate hypercalcemia better. Other causes of the central nervous system symptoms should be ruled out before deciding that they are caused by hypercalcemia alone.
Treatment for hypercalcemia can improve symptoms. Increased urination and thirst, central nervous system symptoms, nausea, vomiting, and constipation improve with treatment more easily than other symptoms, such as loss of appetite, and tiredness. Pain may be more easily controlled once calcium levels are normal. Effective therapy that lowers calcium usually improves symptoms, enhances the quality of life, and may allow the patient to leave the hospital.
After calcium levels return to normal, urine and blood should continue to be checked often to make sure the treatment is still working.
Giving fluids by vein and observing the patient is an accepted treatment for patients with mild hypercalcemia (but no symptoms) and who also have cancer that responds well to anticancer treatment (such as lymphoma, breast cancer, ovarian cancer, head and neck cancers, or multiple myeloma). If the patient has symptoms, or has a cancer that is expected to respond slowly to treatment, then drugs to treat the hypercalcemia should be started. Other treatments should focus on controlling nausea, vomiting, and fever, encouraging continued activity, and limiting use of drugs that cause sleepiness.
Moderate to severe hypercalcemia
Replacing fluids is the first and most important step in treating moderate or severe hypercalcemia. Replacing fluids will not restore normal calcium levels in all patients, but it is still important to do first. The patient's mental state should improve, and nausea and vomiting should decrease within the first 24 hours, but this improvement is only temporary. If cancer therapy (surgery, radiation, or chemotherapy) is not able to be started immediately, then drugs to lower the calcium levels must be used to control the hypercalcemia.
Drugs that may help stop the breakdown of bone include calcitonin, plicamycin (mithramycin), bisphosphonates (etidronate, pamidronate, and clodronate), and gallium nitrate. Steroids and phosphate may also be used to treat hypercalcemia. Dialysis is used as a treatment for hypercalcemia in patients with kidney failure. Other drugs are currently being studied as possible treatments for hypercalcemia. Combinations of drugs may also be used.
Patient and family education
Because hypercalcemia affects quality of life and can be life-threatening if not treated, patients and their caregivers should be aware of the symptoms. They should also learn how to prevent hypercalcemia, what can make it worse, and when to see the doctor.
Even with improved treatment for hypercalcemia, many patients do not survive this complication of cancer. Only effective anticancer therapy improves the patient's chances for long-term survival.
Supportive care includes measures to provide the patient with protection from injury, prevention of fractures, and treatment of symptoms.
Treatment of symptoms is important, especially the prevention of accidental or self-inflicted injury if a patient is confused. Nausea, vomiting, and constipation may also need to be controlled until calcium levels go down. Broken bones may occur due to weakening, so patients need to be moved gently, and falling must be prevented. Activity and weight-bearing exercises should be encouraged. Any new bone pain should be reported so that it can be evaluated for possible fractures.
Supportive care to comfort terminally ill patients and their family members becomes necessary in the last stages of the disease. Changes in the patient's thinking and behavior may especially upset the family.
Usually, treatment of the hypercalcemia will eliminate delirium, agitation, or mental changes, but some patients may need other medications to treat these symptoms. (See the PDQ summary on Cognitive Disorders and Delirium for more information.) Mental changes may take some time to get better, even after calcium levels return to normal.
Lethargy (mental and physical sluggishness) is often a symptom of hypercalcemia. Family members (and sometimes medical staff) may think that the patient is depressed until the actual cause is determined. Most patients will not have symptoms of depression (such as hopelessness, helplessness, guilt, worthlessness, or thoughts of suicide) and instead will appear to be indifferent.
Patients and family members should report symptoms of hypercalcemia such as lethargy, fatigue, confusion, loss of appetite, nausea/vomiting, constipation, and excessive thirst to the health care provider.
Hypercalcemia usually develops as a late complication of cancer, and its appearance is very serious. However, it is not clear if death occurs due to a hypercalcemia crisis (uncontrolled or one that comes back and gets worse) or due to the advanced cancer.
Current Clinical Trials
Check NCI’s list of cancer clinical trials for U.S. supportive and palliative care trials about hypercalcemia of malignancy that are now accepting participants. The list of trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site.
Get More Information From NCI
For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.
The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
Write to us
For more information from the NCI, please write to this address:
NCI Public Inquiries Office
6116 Executive Boulevard, MSC8322
Bethesda, MD 20892-8322
Search the NCI Web site
The NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families. For a quick search, use the search box in the upper right corner of each Web page. The results for a wide range of search terms will include a list of "Best Bets," editorially chosen Web pages that are most closely related to the search term entered.
There are also many other places to get materials and information about cancer treatment and services. Hospitals in your area may have information about local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.
The NCI has booklets and other materials for patients, health professionals, and the public. These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials. Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities. NCI materials on these and other topics may be ordered online or printed directly from the NCI Publications Locator. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237).
Changes to This Summary (08/19/2011)
Editorial changes were made to this summary.
Questions or Comments About This Summary
If you have questions or comments about this summary, please send them to Cancer.gov through the Web site’s Contact Form. We can respond only to email messages written in English.
PDQ is a comprehensive cancer database available on NCI's Web site.
PDQ is the National Cancer Institute's (NCI's) comprehensive cancer information database. Most of the information contained in PDQ is available online at NCI's Web site. PDQ is provided as a service of the NCI. The NCI is part of the National Institutes of Health, the federal government's focal point for biomedical research.
PDQ contains cancer information summaries.
The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries are available in two versions. The health professional versions provide detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions provide current and accurate cancer information.
The PDQ cancer information summaries are developed by cancer experts and reviewed regularly.
Editorial Boards made up of experts in oncology and related specialties are responsible for writing and maintaining the cancer information summaries. The summaries are reviewed regularly and changes are made as new information becomes available. The date on each summary ("Date Last Modified") indicates the time of the most recent change.
PDQ also contains information on clinical trials.
A clinical trial is a study to answer a scientific question, such as whether one method of treating symptoms is better than another. Trials are based on past studies and what has been learned in the laboratory. Each trial answers certain scientific questions in order to find new and better ways to help cancer patients. Some patients have symptoms caused by cancer treatment or by the cancer itself. During supportive care clinical trials, information is collected about how well new ways to treat symptoms of cancer work. The trials also study side effects of treatment and problems that come up during or after treatment. If a clinical trial shows that a new treatment is better than one currently being used, the new treatment may become "standard." Patients who have symptoms related to cancer treatment may want to think about taking part in a clinical trial.
Listings of clinical trials are included in PDQ and are available online at NCI's Web site. Descriptions of the trials are available in health professional and patient versions. Many cancer doctors who take part in clinical trials are also listed in PDQ. For more information, call the Cancer Information Service 1-800-4-CANCER (1-800-422-6237).